InSilico Medicine jumps 10.7% after nominating ISM1354 obesity drug pre-clinical candidate
Shares of InSilico Medicine Cayman TopCo rose 10.7% to HK$61.35, the biggest one-day percentage gain since Sept 18, as it nominated ISM1354 as a pre-clinical candidate for potential obesity intervention and other related disorders.
35, putting the stock on track for its biggest one-day percentage gain since September 18. 9%. InSilico said it nominated ISM1354, a small-molecule Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist, as a pre-clinical candidate for possible intervention in obesity and related disorders, including type 2 diabetes, with potential expansion into cardiovascular diseases. The company said it has announced the nomination of ten pre-clinical candidates in the first nine months of 2026.
4%.